Quintiles Introduces Infosario One Mobile App
RESEARCH TRIANGLE PARK, N.C. – June 16, 2015 – Quintiles,the world’s largest biopharmaceutical services company, is extending its award-winning Quintiles Infosario® technology platform with mobile access to critical clinical trial information. Using the mobile app, key stakeholders in the drug development process can conveniently access site start-up, recruitment and compliance information as well as status updates on data queries and project milestones.
“With so much at stake in the successful delivery of development programs, faster decision making is fundamental,” said Margaret Keegan, senior vice president of Data Sciences & Strategy at Quintiles. “Infosario One provides instant and intuitive access to insights at your fingertips, wherever and whenever you need them.”
The Infosario One mobile app can be personalized with different filters so users can quickly see precisely what’s most important to them. These customized views are then served up in mobile-friendly charts that automatically reflect the latest information.
“Increasing complexity in the delivery of clinical trials - and the related information overload - can slow down progress or obscure valuable information,” said Alejandro Martinez, chief information officer at Quintiles. “We are committed to innovation that simplifies the complex, so this app provides not just easy access but at-a-glance transparency into study progress.”
The Infosario One mobile app will initially be available for download at the Apple App Store.
Quintiles’ experts will demo the app at its booth at the upcoming Drug Information Association (DIA) conference June 14-18, 2015 in Washington, D.C. For more information about Quintiles Infosario One, visit the Quintiles booth at DIA (#601) or www.quintiles.com/infosario-one.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
